Alnylam Pharmaceuticals, Inc. (ALNY) Market Cap & Valuation Ratios
Alnylam Pharmaceuticals, Inc. (ALNY) has a market cap of $30.0B, a trailing P/E of 41.6 and a price-to-sales ratio of 6.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALNYAlnylam Pharmaceuticals, Inc.Follow ALNY — free
—
Price chart with a free account
- Market cap
- 30.0B
- P/E TTM
- 41.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ALNY | 30 | 41.6 | 5.8 | 26.2 | 2.7% | +95% | 21% | 173% |
| RVMD | 40 | — | — | — | -3.1% | — | — | -71% |
| RPRX | 37 | 34.0 | 17.7 | 29.6 | 8.1% | +10% | 60% | 10% |
| ROIV | 26 | — | — | — | -3.1% | -68% | — | -20% |
| INCY | 23 | 14.7 | 3.3 | 10.4 | 8.2% | +27% | 31% | 64% |
| INSM | 20 | — | 17.4 | — | -4.0% | +186% | -74% | -133% |
| EXEL | 16 | 20.3 | 6.2 | 15.2 | 7.3% | +9% | 40% | 47% |
| ASND | 15 | — | — | — | — | +113% | 25% | 11% |
| HALO | 14 | 36.6 | 9.8 | 26.5 | 5.7% | +41% | 36% | 22% |
| JAZZ | 14 | 14.6 | 3.6 | 10.3 | 10.3% | +13% | 19% | 9% |
| BBIO | 13 | — | 21.3 | — | -3.2% | +202% | -70% | — |
| Median of these 10 | 20.3 | 9.8 | 15.2 | 5.7% | +27% | 28% | 10% |
P/E 41.6 vs. a peer median of 20.3; EV/Sales 5.8 vs. 9.8.
Growth vs. price
each dot a company · hover or tap for valuesRVMD and ROIV and INSM and ASND and BBIO have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Alnylam Pharmaceuticals, Inc. — questions
- What is Alnylam Pharmaceuticals, Inc.'s market cap?
- $30.0B.
- What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?
- 41.6 on trailing twelve-month earnings to 2026-06-30.
- What is Alnylam Pharmaceuticals, Inc.'s price-to-sales ratio?
- 6.2.
Every figure on this page comes from Alnylam Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.